Finance

Lists
JBIO:NASDAQ
Jade Biosciences Inc
$23.21
+3.85%
(+0.86) 1D
$23.21
0.00% (0.00)
After hours
Closed: Aug 12, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JBIO...
Open
$22.49
High
$23.46
Low
$21.51
Mkt. cap
1.48B
Avg. vol.
905.32K
Volume
0.00
52-wk high
$27.96
52-wk low
$6.67
EPS
-$2.31
Beta
1.49
Shares outstanding
63.60M
No. of employees
55
Open
$22.49
High
$23.46
Low
$21.51
Mkt. cap
1.48B
Avg. vol.
905.32K
Volume
0.00
52-wk high
$27.96
52-wk low
$6.67
EPS
-$2.31
Beta
1.49
Shares outstanding
63.60M
No. of employees
55
News stories
From web sources and news partners
About Jade Biosciences Inc
CEO-
Employees55
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitejadebiosciences.com
Analyst ratings
Based on 9 analysts giving stock ratings to JBIO in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for JBIO in the last 3 months.
Highest
Current $23.21
$77.00 (+231.75%)
Average
$51.57 (+122.19%)
Lowest
$42.00 (+80.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Akash Tewari
Jefferies
Buy
Maintained
$48.00
+106.8%
08/11/2026
Laura Chico
Wedbush
Buy
Maintained
$47.00
+102.5%
08/11/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$47.00
+102.5%
08/10/2026
Julian Harrison
BTIG
Buy
Maintained
$77.00
+231.8%
08/10/2026
Arthur He CFA
H.C. Wainwright
Buy
Maintained
$55.00
+137%
08/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/10/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$42.00
+81%
08/10/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
08/10/2026
Michael Yee
UBS
Buy
Initiated
$45.00
+93.9%
06/15/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$40.00
+72.3%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.01M
28.54M
36.05M
50.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.39M
6.44M
7.39M
8.85M
Operating expense
27.40M
34.98M
43.44M
58.92M
Total operating expenses
27.40M
34.98M
43.44M
58.92M
Operating income
-27.40M
-34.98M
-43.44M
-58.92M
Other non operating income
-28.00K
20.00K
-9.00K
-62.00K
EBT including unusual items
-25.18M
-31.87M
-40.35M
-55.75M
EBT excluding unusual items
-25.18M
-31.87M
-40.35M
-55.75M
Income tax expense
-
58.00K
16.00K
15.00K
Effective tax rate
-
-0.18%
-0.04%
-0.03%
Other operating expenses
-
-
-
-
Net income
-25.18M
-31.93M
-40.37M
-55.76M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-0.76
Interest and investment income
2.25M
3.08M
3.10M
3.23M
Interest expense
-
-
-
-
Net interest expenses
2.25M
3.08M
3.10M
3.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.39M
-34.97M
-43.44M
-58.91M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps